Genescopy encourages colonoscopy with noninvasive CRC screening test
Click Here to Manage Email Alerts
Geneoscopy Inc. announced favorable results from its CRC-PREVENT trial, which assessed noninvasive, stool-based, at-home screening for colorectal cancer and advanced adenomas.
Geneoscopy’s stool test uses patented RNA biomarker technology to screen for CRC and advanced adenomas that might indicate a higher risk of developing cancer.
“Since the onset of the pandemic, patients’ demand for convenient at-home testing has increased and desire to complete invasive procedures in the office has decreased,” Erica Barnell, PhD, chief scientific officer and co-founder of Geneoscopy, told Healio. “During our clinical trial, we observed a high dropout rate from participants who did not want to complete a colonoscopy due to spikes in COVID outbreaks and we expect this trend to continue.
“Once Geneoscopy commercializes this test, patients who have a negative result from our test will not need a colonoscopy.”
The CRC-PREVENT trial included 8,289 patients aged 45 years and older in the United States from diverse racial, ethnic, geographic, and socioeconomic backgrounds.
The trial found that the efficacy for detecting CRC was 94% sensitivity and 45% sensitivity for detecting advanced adenomas. The trial also found 88% sensitivity for no findings on a colonoscopy.
“Geneoscopy built infrastructure to navigate patients to a local endoscopy center to obtain a colonoscopy as part of the clinical trial,” Barnell said. “Upon launch, we will use this infrastructure to help patients obtain a colonoscopy if a Geneoscopy test is reported as positive.”
Collapse
Read more about
Click Here to Manage Email Alerts